List of Excipients in Branded Drug LABETALOL HCL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	SODIUM CHLORIDE

Generic Drugs Containing LABETALOL HCL

Company	Ingredient	NDC	Excipient
Eon Labs Inc	labetalol hcl	0185-0010	HYPROMELLOSE
Eon Labs Inc	labetalol hcl	0185-0010	LACTOSE MONOHYDRATE
Eon Labs Inc	labetalol hcl	0185-0010	MAGNESIUM STEARATE
Eon Labs Inc	labetalol hcl	0185-0010	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in LABETALOL HCL?

# Of NDCs	Excipient
1	ANHYDROUS DEXTROSE
1	CI 77891
17	CROSPOVIDONE
1	EDETATE DISODIUM

Labetalol HCl Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Labetalol hydrochloride is a mature, low-cost antihypertensive with limited active-ingredient patent risk and substantial formulation opportunity. The strongest commercial opportunities are preservative-free oral liquids, ready-to-use injectable presentations, pediatric and neonatal products, orally disintegrating tablets, and differentiated modified-release systems. The main technical constraints are high oral dose, pH-dependent solubility, bitter taste, variable bioavailability, and the need to control injection pH and osmolality.

What is the pharmaceutical profile of labetalol HCl?

Labetalol HCl is a combined alpha-1 adrenergic antagonist and nonselective beta-adrenergic blocker. It is approved for oral treatment of hypertension and intravenous treatment of severe hypertension, including hypertension associated with pregnancy and acute clinical settings [1,2].

Attribute	Commercial relevance
Active ingredient	Labetalol hydrochloride
Molecular weight	Approximately 364.9 g/mol
Oral strengths	Commonly 100 mg, 200 mg and 300 mg tablets
Injectable strength	Commonly 5 mg/mL
Pharmacology	Alpha-1 blockade plus beta-1 and beta-2 blockade
Oral absorption	Rapid but variable; significant first-pass metabolism
Elimination half-life	Approximately 6 to 8 hours in many adult patients
Main formulation issues	High dose, bitter taste, pH-dependent solubility and variable exposure
Primary dosage forms	Immediate-release tablets and intravenous injection

Labetalol HCl is generally handled as a freely water-soluble salt under acidic conditions. Solubility can decline as pH approaches the neutral range because the molecule contains a basic amine. This property supports acidic oral liquids and injectable solutions but creates precipitation, taste and tolerability risks when the formulation is buffered too close to physiological pH.

What excipients are suitable for labetalol HCl immediate-release tablets?

The most practical immediate-release platform is a conventional compressed tablet using a hydrophilic filler, a superdisintegrant and a low-level lubricant. The formulation should prioritize rapid disintegration without excessive tablet size.

Recommended excipient architecture

Functional role	Candidate excipients	Strategic purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, anhydrous lactose, mannitol	Supports tablet mass and compressibility
Binder	Povidone, copovidone, pregelatinized starch	Improves granule strength and content uniformity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Film coat	Hypromellose, polyethylene glycol, titanium dioxide or approved colorants	Improves handling, identification and swallowability

A direct-compression formulation is commercially attractive because it reduces manufacturing steps and avoids water exposure. Wet granulation may be preferable where the active ingredient has poor flow, poor compressibility or segregation risk. High-dose tablets require particular attention to blend uniformity because the active ingredient represents a large fraction of tablet weight.

Lactose-based formulations may provide low cost and good compactability, but compatibility studies should assess reducing-sugar reactions involving the secondary amine. Microcrystalline cellulose, mannitol and dibasic calcium phosphate can provide alternative platforms where lactose compatibility, moisture sensitivity or patient preference is a concern.

Magnesium stearate should be optimized carefully. Excessive concentration or over-lubrication can slow dissolution and weaken tablet tensile strength. Sodium stearyl fumarate may provide a useful alternative where lubricant sensitivity or faster dissolution is important.

What tablet formulation risks require testing?

The critical development tests are:

1. Blend uniformity at the highest and lowest commercial strengths.
2. Tablet disintegration and dissolution across acidic, intermediate and near-neutral media.
3. Assay and degradation under heat and humidity.
4. Compatibility of labetalol HCl with lactose, starches, alkaline minerals and lubricants.
5. Stability after film coating.
6. Dissolution after scale-up and changes in compression force.

An immediate-release generic should match the reference product's dissolution profile across multiple media rather than relying only on a single pharmacopoeial endpoint. This is particularly important because changes in disintegration, particle size and excipient composition can influence the rate and extent of absorption.

What excipients are suitable for labetalol HCl oral liquids?

An oral solution or suspension has a clear commercial rationale for pediatric, geriatric, dysphagic and hospital use. A true solution is preferable where achievable because it avoids dose-uniformity and sedimentation issues. The acidic solubility of labetalol HCl supports a low-pH formulation.

Oral solution strategy

A practical oral solution can use:

• Purified water as the vehicle.
• Citrate, acetate or another suitable buffer system.
• pH adjustment with hydrochloric acid or another pharmaceutically acceptable acid.
• Glycerin, sorbitol or propylene glycol for mouthfeel and viscosity.
• A suitable preservative system if the product is multidose.
• Flavor and sweetener for taste masking.
• Chelating and antioxidant systems only where justified by stability data.

The target pH should be selected from solubility, stability, preservative efficacy, taste and patient tolerability data. A strongly acidic product may improve chemical and physical stability but can worsen palatability and dental exposure. A formulation near neutral pH may be more acceptable but creates greater risk of precipitation.

Oral suspension strategy

If a concentrated solution cannot be maintained across the intended temperature range, a suspension may provide a more robust product. Candidate suspending agents include xanthan gum, hypromellose, sodium carboxymethylcellulose, microcrystalline cellulose with carboxymethylcellulose sodium and poloxamers.

The suspension should be designed around:

• Rapid redispersion after storage.
• Low sedimentation volume.
• Syringeability through oral dosing devices.
• Dose uniformity throughout the bottle.
• Compatibility with preservatives and flavor systems.
• Controlled viscosity that does not impede pediatric administration.

A 10 mg/mL or 20 mg/mL presentation could reduce dose volume compared with lower-strength liquids, but concentrated products increase taste intensity and precipitation risk. Unit-dose cups or oral syringes would reduce dosing errors and improve hospital use.

What taste-masking excipients are relevant?

Labetalol HCl has a bitter pharmaceutical taste. Useful approaches include:

• High-intensity sweeteners such as sucralose or acesulfame potassium.
• Polyols such as sorbitol, glycerol or mannitol.
• Fruit or mint flavor systems.
• Ion-exchange resins.
• Polymer coating of drug particles.
• Complexation or microencapsulation.

Ion-exchange resin complexes and coated microparticles may provide stronger taste masking than simple sweetening. They also introduce risks involving incomplete release, batch variability and sedimentation. A formulation intended for children should assess taste at the actual dose volume, not only at a diluted laboratory concentration.

What excipients are suitable for labetalol HCl injection?

The established injectable product is an aqueous labetalol HCl solution commonly supplied at 5 mg/mL. The formulation is generally acidic and uses sodium chloride for isotonicity, with pH adjustment as required by the product specification [2,3].

Injectable formulation priorities

Requirement	Formulation implication
Physical clarity	Control pH, concentration and particulate formation
Isotonicity	Sodium chloride or another suitable tonicity agent
Chemical stability	Minimize oxygen, light and temperature stress
Patient tolerability	Control acidity and osmolality
Sterility	Terminal sterilization where feasible, or aseptic processing
Container compatibility	Evaluate glass, cyclic olefin polymer and other systems
Administration	Support dilution and infusion compatibility

A ready-to-use bag, vial or prefilled syringe could improve hospital workflow and reduce compounding errors. The commercial value is highest in emergency departments, intensive-care units, obstetric units and operating rooms.

A ready-to-administer presentation should address:

• Stability after dilution in common infusion fluids.
• Compatibility with common intravenous tubing.
• Adsorption to container and tubing materials.
• Extractables and leachables.
• Particulate control.
• Light protection.
• In-use stability after vial entry or syringe activation.
• Labeling for bolus versus infusion administration.

Preservative-free single-dose packaging is generally preferable for intravenous use. A premixed infusion could be differentiated by concentration, container design, storage condition or extended in-use stability rather than by active ingredient.

What modified-release opportunities exist for labetalol HCl?

Labetalol's several-hour half-life creates a possible rationale for once- or twice-daily modified release. A modified-release product could target adherence, smoother exposure and reduced peak-related adverse effects. The commercial and regulatory risk is higher than for an immediate-release generic because the dosage form changes pharmacokinetics and may require a new clinical bridge.

Candidate technologies

• Hydrophilic HPMC matrix tablets.
• Hydrophobic ethylcellulose or polymethacrylate matrices.
• Multiparticulates in capsules.
• Coated pellets.
• Osmotic delivery systems.
• Layered tablets combining immediate and sustained-release fractions.

A high-dose matrix tablet may become physically large. Multiparticulate systems can improve dose flexibility and reduce the consequences of local defects in the release coating, but they increase manufacturing complexity.

The target profile should avoid an excessive early peak while preserving timely antihypertensive activity. Food-effect testing is important because changes in gastric emptying, bile exposure and gastrointestinal transit may alter release and absorption.

A modified-release product would usually be better positioned through a 505(b)(2) pathway or another applicable regulatory route than through a conventional ANDA if it does not have the same dosage form and release characteristics as the reference product [4].

Can an orally disintegrating tablet create a commercial opportunity?

An orally disintegrating tablet could target patients who have difficulty swallowing conventional tablets. The main obstacle is the 100 mg to 300 mg dose range. A 300 mg ODT may be too large or unpleasant unless the tablet uses a high-load, low-density design.

Suitable excipients include:

• Mannitol for mouthfeel and cooling sensation.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Low-substituted hydroxypropyl cellulose for structure.
• Aspartame, sucralose or acesulfame potassium for sweetness.
• Flavoring agents.
• Silicified microcrystalline cellulose for compressibility.

Taste masking is the decisive issue. A rapidly disintegrating tablet exposes the active ingredient quickly, so a conventional sweetener-only approach may be inadequate. Coated drug particles, resin complexes or multilayer structures may be required.

What pediatric and neonatal products could be commercialized?

Pediatric and neonatal use is one of the more attractive unmet formulation segments. Labetalol is used in pediatric and neonatal hypertension settings, but dose calculations are weight-based and often require extemporaneous compounding or dilution.

Potential products include:

1. A preservative-free oral solution in a unit-dose container.
2. A multidose oral solution with an oral syringe and calibrated adapter.
3. A low-concentration injectable solution for neonatal titration.
4. A ready-to-use infusion bag.
5. A dispersible tablet for older children.

The excipient strategy should avoid unnecessary ethanol, propylene glycol and high preservative loads in neonatal products. Development should include age-appropriate taste, syringe dosing, compatibility with feeding tubes and stability after opening.

A pediatric product can generate commercial differentiation even when the active ingredient is off patent because the value lies in dosing accuracy, hospital procurement, caregiver usability and reduced pharmacy compounding.

What FDA regulatory pathway applies to new labetalol HCl formulations?

A conventional immediate-release tablet that matches the reference product can generally pursue an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality and labeling [4].

A new oral liquid, modified-release product, ODT, prefilled syringe or ready-to-use infusion may require a different regulatory strategy depending on whether the dosage form, strength, route, release profile and labeling match an approved reference.

Product concept	Likely regulatory positioning
Same-strength immediate-release tablet	ANDA pathway if reference criteria are met
Oral solution with different concentration	ANDA or other pathway depending on listed reference and sameness
New modified-release tablet	505(b)(2) risk is more likely
Pediatric formulation with new excipients or concentration	Product-specific FDA assessment
Ready-to-use IV bag	ANDA if pharmaceutically equivalent; otherwise potentially 505(b)(2)
Prefilled syringe	Device, container-closure and drug-product requirements
Novel delivery system	505(b)(2) or new-drug development pathway

The FDA Inactive Ingredient Database is important when selecting excipients and maximum daily exposure levels. A formulation using an excipient in a new route, concentration or dosage form may require additional safety justification [5].

What is the Orange Book and patent status of labetalol HCl?

Labetalol is a mature small-molecule product. The original active-ingredient and early product exclusivities are long expired. Commercial competition is therefore driven primarily by manufacturing cost, regulatory execution, supply reliability, dosage-form differentiation and contracting.

For a current product launch, the sponsor should confirm:

• The current Orange Book reference listed drug.
• Any active listed patents.
• Any pediatric exclusivity or regulatory exclusivity.
• Current ANDA approvals.
• The applicable labeling and dosage-form requirements.
• Paragraph IV certifications associated with any relevant listed patents.

Novel formulation patents could cover release profiles, particle coatings, taste-masking systems, ready-to-use packaging, stability improvements or specific excipient combinations. Their strength would depend on claim construction, written description, enablement, unexpected results and obviousness. Broad claims directed only to routine excipient substitution would face greater validity risk than claims supported by distinctive pharmacokinetics, stability or clinical performance.

Which companies are challenging labetalol HCl, and what litigation affects the market?

The market is primarily generic. The relevant competitive set includes manufacturers with approved labetalol tablets and injection, contract manufacturers capable of sterile filling, and hospital suppliers offering premixed intravenous products.

There is no strategic basis for assuming that an old active ingredient is free of all formulation or manufacturing patents. A launch assessment should examine U.S. Patent and Trademark Office records, FDA Orange Book listings, court dockets and product-specific ANDA litigation. Paragraph IV risk is most relevant where a competitor introduces a differentiated formulation with active patents, not where the product is a conventional unmodified generic.

Settlement agreements, if any, should be reviewed for launch dates, authorized-generic provisions, supply rights, manufacturing restrictions and geographic scope. These terms can materially affect the commercial value of a formulation even when the underlying active ingredient has no meaningful exclusivity.

How strong is the commercial opportunity for labetalol HCl?

Opportunity	Technical difficulty	Differentiation	Commercial potential
Conventional tablets	Low	Low	Moderate, cost-driven
Generic injection	Moderate	Low to moderate	Moderate, hospital supply-driven
Ready-to-use IV bag	Moderate to high	High	High in institutional channels
Prefilled syringe	High	High	Moderate to high
Pediatric oral solution	Moderate	High	High in specialty channels
Neonatal preservative-free product	High	High	Moderate to high
ODT	Moderate	Moderate	Moderate
Modified-release tablet	High	High	Moderate to high
Taste-masked suspension	Moderate	High	Moderate

The strongest near-term opportunity is a reliable, preservative-free, ready-to-administer injectable presentation supported by hospital workflow data. The strongest outpatient opportunity is a stable, palatable pediatric oral liquid with an accurate dosing device.

What manufacturing and intellectual-property barriers should be expected?

The main manufacturing barriers are not synthesis of labetalol HCl but control of the finished dosage form.

Oral products

• High-dose tablet compression.
• Blend segregation.
• Dissolution control.
• Taste masking.
• pH-dependent precipitation in liquids.
• Microbial control in multidose products.
• Stability after opening.

Injectable products

• Sterile filling capacity.
• Particulate control.
• Container compatibility.
• Dilution stability.
• Terminal sterilization feasibility.
• Extractables and leachables.
• Supply-chain reliability for hospital procurement.

Intellectual-property barriers

Potential protectable features include:

• Specific sustained-release profiles.
• Coated particle systems.
• Taste-masked labetalol particles.
• Stable concentrated solutions.
• Ready-to-use IV containers.
• Low-silicone or low-adsorption syringe systems.
• Pediatric dosing packages.
• Manufacturing processes that produce a distinctive impurity profile or stability result.

Patent value will depend on whether the claims capture a commercially important product and withstand obviousness scrutiny. Regulatory exclusivity, trade secrets and manufacturing know-how may be more valuable than broad formulation patents for a mature compound.

Key Takeaways

• Labetalol HCl is a mature generic active ingredient with limited original-drug exclusivity value.
• Immediate-release tablets remain the lowest-risk and lowest-differentiation opportunity.
• Acidic oral liquids are technically feasible but require careful control of precipitation, taste and preservative performance.
• Pediatric and neonatal products offer the clearest unmet formulation need.
• Ready-to-use intravenous products can create hospital-channel value through workflow and safety improvements.
• Modified-release and ODT products offer differentiation but carry greater development and regulatory risk.
• Excipient selection should be driven by pH, high dose, taste, dissolution, sterility and route-specific tolerability.
• Current Orange Book listings, ANDA competition, Paragraph IV certifications and formulation patents require product-specific verification before investment or launch decisions.

FAQs About Labetalol HCl Formulation and Commercialization

What is the best excipient for labetalol HCl tablets?

No single excipient is universally optimal. A practical platform uses microcrystalline cellulose or lactose with crospovidone or croscarmellose sodium, povidone where binding is needed, colloidal silicon dioxide and a low level of magnesium stearate.

Can labetalol HCl be formulated as an oral solution?

Yes. An acidic aqueous solution is technically feasible because labetalol HCl has greater solubility at lower pH. The main development issues are taste, precipitation at higher pH, preservative efficacy and stability after opening.

Is labetalol HCl suitable for a sustained-release product?

Yes, in principle. Its several-hour half-life provides a pharmacokinetic rationale, but the high dose and need to establish a reliable release profile make modified-release development more complex than an immediate-release generic.

What is the best commercial formulation for hospitals?

A preservative-free ready-to-use injection, prefilled syringe or premixed infusion can provide the strongest differentiation. The product should reduce dilution, calculation and compounding steps while maintaining compatibility and stability.

Are labetalol HCl formulation patents commercially valuable?

They can be valuable when they protect a differentiated release profile, stable concentrated solution, taste-masking system, pediatric product or ready-to-use injectable presentation. Routine excipient substitutions are less likely to support durable patent protection.

References

1. U.S. Food and Drug Administration. (2024). Labetalol hydrochloride prescribing information. FDA/DailyMed.

2. DailyMed. (2024). Labetalol hydrochloride injection and tablets: labeling information. National Library of Medicine.

3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Labetalol hydrochloride and labetalol hydrochloride injection monographs. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.